No CrossRef data available.
Article contents
Do Results of Surveillance Cultures Impact the Choice of Empirical Antibiotics Among Patients with Carbapenem-Resistant Acinetobacter baumannii Infections?
Published online by Cambridge University Press: 10 September 2015
Abstract
We aimed to determine whether the results of surveillance cultures were associated with use of appropriate empirical antibiotic therapy among patients with carbapenem-resistant Acinetobacter baumannii infections. We found that surveillance status was not associated with appropriate empirical antibiotic therapy (P=.36). There were significant delays to concordant therapy among surveillance-positive patients (P=.03).
Infect. Control Hosp. Epidemiol. 2015;36(12):1455–1457
- Type
- Concise Communications
- Information
- Copyright
- © 2015 by The Society for Healthcare Epidemiology of America. All rights reserved
References
REFERENCES
1.
Munoz-Price, LS, Weinstein, RA.
Acinetobacter infection. N Engl J Med
2008;358:1271–1281.CrossRefGoogle ScholarPubMed
2.
Chopra, T, Marchaim, D, Awali, RA, et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother
2013;57:6270–6275.CrossRefGoogle ScholarPubMed
3.
Lee, HY, Chen, CL, Wu, SR, Huang, CW, Chiu, CH. Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med
2014;42:1081–1088.CrossRefGoogle ScholarPubMed
4.
Latibeaudiere, R, Rosa, R, Laowansiri, P, Arheart, K, Namias, N, Munoz-Price, LS. Surveillance cultures growing carbapenem-resistant Acinetobacter baumannii predict the development of clinical infections: a retrospective cohort study. Clin infect Dis
2015;60:415–422.CrossRefGoogle ScholarPubMed
5.
Munoz-Price, LS, Namias, N, Cleary, T, et al.
Acinetobacter baumannii: association between environmental contamination of patient rooms and occupant status. Infect Control Hosp Epidemiol
2013;34:517–520.CrossRefGoogle ScholarPubMed
6.
Horan, TC, Andrus, M, Dudeck, MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control
2008;36:309–332.CrossRefGoogle ScholarPubMed
7.
Centers for Diseases Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/. Published 2013. Accessed February 2, 2014.Google Scholar
8.
Shlaes, DM, Sahm, D, Opiela, C, Spellberg, B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother
2013;57:4605–4607.CrossRefGoogle ScholarPubMed
9.
Spellberg, B, Bonomo, RA. The deadly impact of extreme drug resistance in Acinetobacter baumannii
. Crit Care Med
2014;42:1289–1291.CrossRefGoogle ScholarPubMed
10.
Rosa, R, Arheart, KL, Depascale, D, et al. environmental exposure to carbapenem-resistant Acinetobacter baumannii as a risk factor for patient acquisition of A. baumannii
. Infect Control Hosp Epidemiol
2014;35:430–433.CrossRefGoogle ScholarPubMed